Teleflex (NYSE:TFX) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS

Key Points

• Teleflex beat quarterly expectations, reporting adjusted EPS of $1.76 versus the $1.28 consensus and revenue of $570.3 million versus $559.6 million expected. Revenue increased 28.9% year over year, though GAAP EPS declined to $0.96 from $1.54.
• The company raised fiscal 2026 adjusted EPS guidance to $6.90–$7.20 from $6.25–$6.55, but lowered its revenue-growth outlook to 3.5%–4.5% as integration of its Vascular Intervention acquisition takes longer than expected.
• Teleflex completed its approximately $1.5 billion OEM divestiture, using $700 million of proceeds to repay debt and planning additional share repurchases. It also highlighted FDA approval for EZPLAZ plasma and progress on the Freesolve vascular scaffold program.

Teleflex (NYSE:TFX - Get Free Report) posted its quarterly earnings data on Thursday. The medical technology company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.28 by $0.48, FiscalAI reports. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. During the same quarter last year, the company earned $3.73 earnings per share. The business's revenue for the quarter was up 28.9% compared to the same quarter last year. Teleflex updated its FY 2026 guidance to 6.900-7.200 EPS.

Here are the key takeaways from Teleflex's conference call:

• Second-quarter results exceeded expectations, with pro forma adjusted constant-currency revenue growth of 4.7% and adjusted EPS of $1.76, supported by strong vascular and surgical performance.
• Teleflex lowered its 2026 revenue-growth outlook to 3.5%-4.5% from 4.5%-5.5%, primarily because integration of the Vascular Intervention acquisition is taking longer than expected and is now expected to continue through the second half of the year.
• The company raised 2026 adjusted EPS guidance to $6.90-$7.20 from $6.25-$6.55, reflecting share repurchases, lower projected interest expense, and a reduced tax-rate outlook, while maintaining an adjusted operating-margin outlook of approximately 19%.
• Teleflex closed the OEM divestiture for approximately $1.5 billion in proceeds and used much of the after-tax proceeds to repay $700 million of debt; it also plans to begin an additional $250 million accelerated share repurchase and remains committed to $1 billion of buybacks and $800 million of debt reduction.
• Innovation milestones included FDA approval of EZPLAZ freeze-dried plasma and continued progress for the Freesolve resorbable magnesium scaffold, including early completion of BIOMAG-II enrollment and commencement of the U.S. pivotal BIOMAG-III trial.

Teleflex Price Performance

TFX stock traded up $2.83 during midday trading on Thursday, hitting $139.61. The company's stock had a trading volume of 1,301,231 shares, compared to its average volume of 800,740. Teleflex has a 12 month low of $100.18 and a 12 month high of $145.00. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $6.18 billion, a price-to-earnings ratio of -6.12, a price-to-earnings-growth ratio of 1.04 and a beta of 0.81. The company has a 50 day moving average of $131.41 and a two-hundred day moving average of $122.20.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex's payout ratio is currently -5.96%.

Key Headlines Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Q2 earnings and revenue exceeded estimates. Teleflex reported adjusted diluted EPS of $1.76, well above the $1.28 consensus estimate, while revenue from continuing operations reached $570.3 million versus expectations of $559.6 million. Revenue rose 28.9% year over year, or 4.7% on a pro forma adjusted constant-currency basis. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year EPS guidance was raised or set above consensus. Teleflex provided fiscal 2026 adjusted EPS guidance of $6.90-$7.20, compared with the $6.70 analyst consensus. Its revenue outlook of approximately $2.3 billion was broadly in line with expectations, reducing the risk of a sales shortfall. Teleflex Reports Second Quarter Results and Full-Year Outlook
• Neutral Sentiment: The OEM divestiture is reshaping Teleflex. Teleflex completed the $1.5 billion sale of its medical OEM business, now operating as INGENYX. The transaction may strengthen financial flexibility and sharpen focus on core medical technologies, although the business sale also changes the company’s revenue and earnings base. Teleflex Completes Sale of OEM Business
• Negative Sentiment: Reported GAAP profitability weakened year over year. GAAP diluted EPS from continuing operations was $0.96, down from $1.54 a year earlier, despite the adjusted EPS beat. The company also continues to report a negative net margin, which may temper the market’s reaction to the strong adjusted results. Teleflex Earnings Report

Wall Street Analysts Forecast Growth

TFX has been the subject of several analyst reports. BMO Capital Markets started coverage on shares of Teleflex in a report on Wednesday, July 8th. They issued an "outperform" rating and a $159.00 target price for the company. Piper Sandler upgraded shares of Teleflex from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $140.00 to $160.00 in a research report on Monday, June 8th. Weiss Ratings reissued a "sell (d)" rating on shares of Teleflex in a research note on Wednesday, June 24th. Raymond James Financial restated an "outperform" rating and set a $150.00 price objective on shares of Teleflex in a research report on Friday, May 8th. Finally, UBS Group began coverage on shares of Teleflex in a research note on Tuesday, July 28th. They set a "neutral" rating and a $145.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $148.90.

Hedge Funds Weigh In On Teleflex

A number of hedge funds and other institutional investors have recently modified their holdings of TFX. Coldstream Capital Management Inc. bought a new stake in Teleflex in the third quarter worth $215,000. Advisory Services Network LLC bought a new position in Teleflex in the 3rd quarter valued at $142,000. Northwestern Mutual Wealth Management Co. increased its stake in Teleflex by 213.5% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 1,759 shares of the medical technology company's stock worth $215,000 after purchasing an additional 1,198 shares during the period. Perbak Capital Partners LLP bought a new stake in shares of Teleflex during the third quarter worth $205,000. Finally, Quadrant Capital Group LLC bought a new stake in shares of Teleflex during the third quarter worth $166,000. Institutional investors own 95.62% of the company's stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source